Navigation Links
Leading Prostate Cancer Group Says New Drug Gives Hope To Men With Advanced Prostate Cancer
Date:9/4/2012

DENVER, Sept. 4, 2012 /PRNewswire-USNewswire/ -- Leading prostate cancer group, the Prostate Conditions Education Council (PCEC), applauds today's approval by the United States Food and Drug Administration (FDA) of a groundbreaking new therapy, Xtandi, formerly known as MDV3100. The drug has shown promise in clinical trials, extending the life of men with advanced prostate cancer even following other treatments. 

"This new therapy represents an important advancement in the treatment of prostate cancer, extending survival in patients who failed previous chemotherapy for castration-resistant disease," said Daniel Petrylak, M.D., PCEC council member and director of the genitourinary oncology program and co-director of the signal transduction program at the Yale University Cancer Center.

The PCEC, a national organization committed to men's health and a leader in supporting prostate cancer research and treatment, has been working for several decades to improve treatment options.  New treatments like Xtandi - an antiandrogen therapy that acts to block testosterone, slowing prostate cancer growth - are bringing new hope to men with prostate cancer.

"Since our work with antiandrogens began over two decades ago, we have been waiting for a superior agent that shows promise for late-stage patients; we have it with the approval of Xtandi," said E. David Crawford, M.D. head of the urologic oncology department at the University of Colorado Health Sciences Center, and founder/chairman of the PCEC.  "I am confident that this is only the beginning of success stories with this agent and that it will be used in earlier stages of prostate cancer in the near future. While this therapy is an innovative development for patients in the late stages of prostate cancer, early detection and treatment are key to survival. Continued efforts to improve awareness and education of the disease are still very important and support efforts to diagnose and treat the disease before it reaches the advance stages."

Prostate cancer remains the second leading cause of cancer death among American men[i], and can be an aggressive disease that is most successfully treated when detected early on. Each year, the PCEC holds Prostate Cancer Awareness Week, dedicated to offering free or low-cost screenings for more than 125,000 men across the U.S. and internationally. This year, the week is being held September 16-22. Since the first PCAW in 1989, the program has helped to screen nearly five million men in the U.S., and this number continues to grow each year both at home and internationally.

About the Prostate Conditions Education Council

A national organization committed to men's health, the Prostate Conditions Education Council (PCEC) is the nation's leading resource for information on prostate health. The PCEC is dedicated to saving lives through awareness and the education of men, the women in their lives, as well as the medical community about prostate cancer prevalence, the importance of early detection, and available treatment options, as well as other men's health issues. The Council – comprised of a consortium of leading physicians, health educators, scientists and prostate cancer advocates – aims to conduct nationwide screenings for men and perform research that will aid in the detection and treatment of prostate conditions. More information is available at www.prostateconditions.org

[i] http://www.cdc.gov/cancer/dcpc/data/men.htm


'/>"/>
SOURCE Prostate Conditions Education Council
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
2. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
3. Industry Leading Pharmaceutical News Website in-Pharmatechnologist.com Refocused and Relaunched
4. Remedy Informatics Named "Cool Vendor" in Life Sciences by Leading Technology Analyst Firm
5. PeaceHealth Laboratories New Patent Addresses a Leading Cause of Death: Prescription Drug Abuse
6. Software Pioneer Leaves $10 Million Bequest To Five Leading Non-profits In Health And Drug Policy Reform
7. Leading Pension Annuity Provider Legal & General, Celebrates 175 Years
8. Denton Vacuum Ships Breakthrough Wafer-level Optics Development System to Leading German R&D Organization
9. FMC Corporation Acquires Phytone, Ltd., a Leading European Natural Colors Business
10. Court Preliminarily Deems Millennium Laboratories Press Release Misleading
11. AstraZeneca and Leading Academic Scientists to Collaborate on Alzheimers Disease Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 25, 2016 , ... Austin residents seeking Mohs surgery services, can now turn ... to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization ... selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions today ... cultivation and processing operations at its production facility, and opened its first two ... the manufacturer of a complete system of proactive air and surface purification solutions ...
Breaking Medicine News(10 mins):